PMID- 28881719
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20170925
LR  - 20230808
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 32
DP  - 2017 Aug 8
TI  - Combined CT-guided radiofrequency ablation with systemic chemotherapy improves 
      the survival for nasopharyngeal carcinoma with oligometastasis in liver: 
      Propensity score matching analysis.
PG  - 52132-52141
LID - 10.18632/oncotarget.10383 [doi]
AB  - The aim of this study was to retrospectively compare the treatment efficacy of 
      systemic chemotherapy combined with sequential CT-guided radiofrequency ablation 
      (Chemo-RFA) to chemotherapy alone (Chemo-only) in the management of 
      nasopharyngeal carcinoma (NPC) with liver metastasis. Between 2003 and 2011, 328 
      NPC patients diagnosed with liver metastasis at Sun Yat-sen University Cancer 
      Center were enrolled. One-to-one matched pairs between Chemo-RFA group with the 
      Chemo-only group were generated using propensity score matching. The associations 
      of treatment modality with overall survival (OS) and progression-free survival 
      (PFS) were determined by Cox regression. Of the patients enrolled, 37 patients 
      (11.8 %) received combined treatment, 291 (82.2) received chemotherapy alone. The 
      patients in Chemo-RFA group were more frequently classified as lower number (</=3) 
      of liver metastatic lesions (P<0.001), had lower rates of bi-lobar liver 
      metastasis (P<0.001) and extra-hepatic metastasis (P<0.001) than patients in 
      Chemo-only group. After propensity score matching, 37 pairs of well-matched liver 
      metastatic NPC patients were selected from different treatment groups. The 
      adjusted hazard ratio in OS and PFS of the choice for Chemo-RFA approach to 
      Chemo-only was 0.53 (95%CI, 0.30-0.93) and 0.60 (95%CI, 0.36-0.97), respectively. 
      In conclusion, combined CT-guided RFA and chemotherapy approach offer the chance 
      of improved survival for NPC patients with oligometastasis in liver, and should 
      be considered if the ablation is technically feasible.
FAU - Li, Wang
AU  - Li W
AD  - Department of Medical Imaging and Interventional Radiology, Sun Yat-sen 
      University Cancer Center, State Key Laboratory of Oncology in South China, 
      Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 51060, 
      P. R. China.
FAU - Bai, Yutong
AU  - Bai Y
AD  - Zhong Shan Medical School, Sun Yat-sen University, Guangzhou 510080, People's 
      Republic of China.
FAU - Wu, Ming
AU  - Wu M
AD  - Zhong Shan Medical School, Sun Yat-sen University, Guangzhou 510080, People's 
      Republic of China.
FAU - Shen, Lujun
AU  - Shen L
AD  - Department of Medical Imaging and Interventional Radiology, Sun Yat-sen 
      University Cancer Center, State Key Laboratory of Oncology in South China, 
      Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 51060, 
      P. R. China.
FAU - Shi, Feng
AU  - Shi F
AD  - Department of Medical Imaging and Interventional Radiology, Sun Yat-sen 
      University Cancer Center, State Key Laboratory of Oncology in South China, 
      Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 51060, 
      P. R. China.
FAU - Sun, Xuqi
AU  - Sun X
AD  - Zhong Shan Medical School, Sun Yat-sen University, Guangzhou 510080, People's 
      Republic of China.
FAU - Lin, Caijin
AU  - Lin C
AD  - Zhong Shan Medical School, Sun Yat-sen University, Guangzhou 510080, People's 
      Republic of China.
FAU - Chang, Boyang
AU  - Chang B
AD  - Department of Medical Imaging and Interventional Radiology, Sun Yat-sen 
      University Cancer Center, State Key Laboratory of Oncology in South China, 
      Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 51060, 
      P. R. China.
FAU - Pan, Changchuan
AU  - Pan C
AD  - Department of Medical Oncology, Sichuan Cancer Hospital and Institute, Second 
      People's Hospital of Sichuan Province, Chengdu, Sichuan 610041, P. R. China.
FAU - Li, Zhiwen
AU  - Li Z
AD  - Zhong Shan Medical School, Sun Yat-sen University, Guangzhou 510080, People's 
      Republic of China.
FAU - Wu, Peihong
AU  - Wu P
AD  - Department of Medical Imaging and Interventional Radiology, Sun Yat-sen 
      University Cancer Center, State Key Laboratory of Oncology in South China, 
      Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 51060, 
      P. R. China.
LA  - eng
GR  - R01 AA022701/AA/NIAAA NIH HHS/United States
PT  - Journal Article
DEP - 20160702
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5581018
OTO - NOTNLM
OT  - Nasopharyngeal carcinoma
OT  - liver metastasis
OT  - palliative chemotherapy
OT  - prognosis
OT  - radiofrequency ablation
COIS- CONFLICTS OF INTEREST The authors declare no conflicts of interest.
EDAT- 2016/07/02 00:00
MHDA- 2016/07/02 00:01
PMCR- 2017/08/08
CRDT- 2017/09/09 06:00
PHST- 2016/02/25 00:00 [received]
PHST- 2016/06/09 00:00 [accepted]
PHST- 2017/09/09 06:00 [entrez]
PHST- 2016/07/02 00:00 [pubmed]
PHST- 2016/07/02 00:01 [medline]
PHST- 2017/08/08 00:00 [pmc-release]
AID - 10383 [pii]
AID - 10.18632/oncotarget.10383 [doi]
PST - epublish
SO  - Oncotarget. 2016 Jul 2;8(32):52132-52141. doi: 10.18632/oncotarget.10383. 
      eCollection 2017 Aug 8.